http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Genprex (GNPX) Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
-
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
-
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
-
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Genprex (GNPX) Announces 1.54M Share Offering at $4.215/sh
-
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Genprex (GNPX) Announces $6.5 Million Registered Direct Offering of Common Stock, Warrants
-
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Genprex (GNPX) Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
-
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
-
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 202
-
Genprex (GNPX) Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
-
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
-
Genprex to Present at Upcoming BIO CEO & Investor Conference
-
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
-
Genprex (GNPX) Announces 1:40 Reverse Stock Split
-
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
-
Genprex (GNPX) Provides Business Update and Outlook for 2024
-
Genprex Provides Business Update and Outlook for 2024
-
Genprex to Present at BIO-Europe 2023 Conference
-
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
-
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Genprex to Present at Upcoming September Investor Conference
-
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs
-
Genprex (GNPX) Granted FDA Orphan Drug Designation for REQORSA
-
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer
-
Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Genprex (GNPX) sells 7.425M shares at $1.01 w/warrants
-
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Genprex (GNPX) Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
-
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
-
Genprex (GNPX) Granted Chinese Patent for REQORSA Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
-
Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
-
Genprex (GNPX) Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for Treatment of Small Cell Lung Cancer
-
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
-
Genprex (GNPX) Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA in Combination with Tagrisso® in Advanced NSCLC
-
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
-
Genprex (GNPX) Publishes Positive Data from Phase 1 Portion of Acclaim-1 Trial Evaluating REQORSA
-
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
-
Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System
-
Genprex to Participate and Present at Upcoming May Industry and Investor Conferences
-
Genprex (GNPX) Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX
-
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting
-
Genprex (GNPX) Reports Independent Research Showing TUSC2 Functions as a Novel Tumor Suppressor for Glioblastoma
-
Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma
-
Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies
-
Genprex to Present at Bioprocessing Summit Conference
-
Genprex to Participate in March Investor and Industry Conferences
-
Genprex (GNPX) Announces 3.81M Share Placement at $1.05/sh
-
Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor
